Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GlaxoSmithKline
Lamotrigine found effective for maintenance treatment of bipolar I disorder
May 14th, 2003
New study results found lamotrigine was effective in delaying the relapse/recurrence of any mood episode in bipolar I patients who had recently experienced and been treated for an acute manic or hypomanic episode. The findings, from one of the longest and largest trials ever conducted in bipolar disorder, point to the therapeutic effects of lamotrigine in the maintenance treatment of bipolar I disorder. This 18-month study assessed the safety and efficacy of GlaxoSmithKline's Lamictal (lamotrigine) and lithium compared with placebo in delaying the relapse/recurrence of any mood episode (depression, mania, hypomania, mixed states) in adult patients...
Source: Biotech Week (2003-05-14)
|
